Harvard's Wyss Institute and AstraZeneca announce collaboration on Organs-on-Chips for drug safety

The Wyss Institute and Astrazeneca will apply the Institute's advances in the development and validation of human organs-on-chips (such as the one shown here) to develop new animal versions. Credit: Alison Reggio/Wyss Institute

Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and AstraZeneca announced a collaboration that will leverage the Institute's Organs-on-Chips technologies to better predict safety of drugs in humans.

Human Organs-on-Chips are composed of a clear, flexible polymer about the size of a computer memory stick, and contain hollow microfluidic channels lined by living human cells—allowing researchers to recreate the physiological and mechanical functions of the organ, and to observe what happens in real time. The goal is to provide more predictive and useful measures of the efficacy and safety of potential new drugs in humans—which could represent an important step in reducing the need for traditional .

The collaboration with AstraZeneca will apply the Institute's advances in the development and validation of human organs-on-chips to develop new animal versions. These animal organs-on-chips will be tested alongside the human models to further understand the extent to which results in animals can predict how an investigational drug might impact humans. The testing of a potential new medicine on animals is a small but necessary step in bringing this medicine to market. Regulators require safety data from animal studies before giving the required approval to test a new medicine in humans. However, animal tests do not always accurately predict what will happen in humans.

"Comparing and animal organs-on-chips is an exciting example of what we call 'predictive science,' in which we harness the power of technology to better understand how a medicine might ultimately impact patients and in some cases speed the delivery of innovative new medicines," said Stefan Platz, Vice President Drug Safety and Metabolism at AstraZeneca. "The Wyss Institute's technology could play a critical role in both improving patient safety and reducing the need for animal testing."

In February, Wyss Founding Director Don Ingber, M.D., Ph.D., who leads the Organs-on-Chips research program, received the prestigious 3Rs Prize from the UK's National Centre for the Replacement, Refinement and Reduction of Animals in Research for the lung-on-a-chip. In March the Society of Toxicology awarded him the Leading Edge in Basic Science Award for his "seminal scientific contributions and advances to understanding fundamental mechanisms of toxicity."

"This collaboration with AstraZeneca will help us to validate this approach as a potential alternative to animal testing by carrying out direct comparisons between organ chips containing cells from animals versus humans in organ-mimicking environments," said Ingber. "If successful, this effort should lead to ways to streamline the drug development process and more effectively predict the of drugs and chemicals in humans."

add to favorites email to friend print save as pdf

Related Stories

Army, academia develop human-on-a-chip technology

Sep 30, 2013

There was a time when the thought of manufacturing organs in the laboratory was science fiction, but now that science is a reality. Army Scientists at the Edgewood Chemical Biological Center and academia ...

Recommended for you

The human race evolved to be fair for selfish reasons

9 hours ago

"Make sure you play fairly," often say parents to their kids. In fact, children do not need encouragement to be fair, it is a unique feature of human social life, which emerges in childhood. When given the o ...

Non-stop PET/CT scan provides accurate images

Sep 18, 2014

Siemens is improving PET/CT imaging and data quality while reducing radiation exposure. The Biograph mCT Flow PET/CT scanner is a new positron emission tomography/computed tomography (PET/CT) system that, ...

Experts: Chopin's heart shows signs of TB

Sep 17, 2014

The preserved heart of composer Frederic Chopin contains signs of tuberculosis and possibly some other lung disease, medical experts said Wednesday.

User comments